NV-NTT
13.5.2020 10:44:08 CEST | Business Wire | Press release
The city of Las Vegas and NTT Corporation (NTT) today announced the Accelerate Smart project has expanded to include two new locations – the city’s Community Healing Garden and a portion of Las Vegas Boulevard at South Main Street and East St. Louis Avenue. As part of the partnership, NTT and the city plan to further expand the smart cities project to Bob Baskin Park, Rotary Park, Stupak Park and Ethel Pearson Park this summer before adding six additional parks by the end of 2020.
Following the success of the initial pilot , which has improved traffic congestion and wrong way driving, NTT will expand the project to provide real-time alerts of safety conditions and maintenance issues to improve public safety and provide a better experience for citizens and visitors. The city’s Smart Park Initiative is designed to increase public safety, while providing awareness of activity to generate usage and operations benchmarks that allow leadership to make more informed decisions.
In total, high-definition optical and audio sensors will now be deployed at 14 locations across the city, which enable an automated system to notify law enforcement and maintenance personnel of safety hazards, such as large crowds, gunshots, breaking glass and vandalism.
“Cities that learn, understand and invest in technology will be the cities of the future, and Las Vegas is at the forefront of innovation,” said Michael Sherwood, Director of Innovation and Technology, city of Las Vegas. “Our Smart Cities pilot has been such a success that we are excited to expand the program to several new locations in the heart of our city, which will continue to improve the lives of our residents and visitors.”
The initial proof of concept provided information to city personnel to increase situational awareness and provide a foundation for traffic management. With the expansion of the smart cities project, Las Vegas will leverage a dashboard to access and view sensors, data streams and analytics. The timely alerts and predictions enable the city to monitor and review events and allow them to dispatch safety and maintenance personnel in a timely manner.
The NTT Accelerate Smart data platform is a secure, distributed platform that captures data via sensors and micro data centers in the designated areas through video and sound, while also integrating historical data sources such as crime, weather and social media. By leveraging cognitive analytics, including machine learning technologies, the system learns normal patterns and can detect and alert authorities of patterns that appear abnormal.
“As we accelerate our smart cities project in Las Vegas, it demonstrates how a more connected society directly benefits citizens,” said Bill Baver, Go to Market Leader, Smart World Team, NTT. “Cities like Las Vegas are capitalizing on successful pilots and beginning to imagine the benefits these technologies can have for their residents and visitors. However, smart is not confined to city limits, as it also extends to stadiums, shopping malls and manufacturing facilities by leveraging similar concepts that have been proven successful in Las Vegas.”
The Accelerate Smart solution deployed in Las Vegas is built on NTT’s innovative Cognitive Foundation™ architecture, which enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways, as well as virtualization software hosting predictive analytics applications.
The partnership with NTT is part of the city of Las Vegas’ charter in becoming a smart city to provide safe, reliable and efficient civic technology that stimulates economic growth. To learn more about the Smart Cities initiative in Las Vegas, visit NTT’s website and watch the case study on YouTube .
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005261/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom